biomarker (medicine) biomarker (medicine) in medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. more generally a biomarker is anything that can be used as an indicator of a particular disease state or some other physiological state of an organism. according to the who, the indicator may be chemical, physical, or biological in nature - and the measurement may be functional, physiological, biochemical, cellular, or molecular. a biomarker can be a substance that is introduced into an organism as a means to examine organ function or other aspects of health. for example, rubidium chloride is used in isotopic labeling to evaluate perfusion of heart muscle. it can also be a substance whose detection indicates a particular disease state, for example, the presence of an antibody may indicate an infection. more specifically, a biomarker indicates a change in expression or state of a protein that correlates with the risk or progression of a disease, or with the susceptibility of the disease to a given treatment. biomarkers can be characteristic biological properties or molecules that can be detected and measured in parts of the body like the blood or tissue. they may indicate either normal or diseased processes in the body. biomarkers can be specific cells, molecules, or genes, gene products, enzymes, or hormones. complex organ functions or general characteristic changes in biological structures can also serve as biomarkers. although the term biomarker is relatively new, biomarkers have been used in pre-clinical research and clinical diagnosis for a considerable time. for example, body temperature is a well-known biomarker for fever. blood pressure is used to determine the risk of stroke. it is also widely known that cholesterol values are a biomarker and risk indicator for coronary and vascular disease, and that c-reactive protein (crp) is a marker for inflammation. biomarkers are useful in a number of ways, including measuring the progress of disease, evaluating the most effective therapeutic regimes for a particular cancer type, and establishing long-term susceptibility to cancer or its recurrence. the parameter can be chemical, physical or biological. in molecular terms biomarker is "the subset of markers that might be discovered using genomics, proteomics technologies or imaging technologies. biomarkers play major roles in medicinal biology. biomarkers help in early diagnosis, disease prevention, drug target identification, drug response etc. several biomarkers have been identified for many diseases such as serum ldl for cholesterol, blood pressure, and p53 gene and mmps as tumor markers for cancer. disease-related biomarkers and drug-related biomarkers it is necessary to distinguish between disease-related and drug-related biomarkers. disease-related biomarkers give an indication of the probable effect of treatment on patient (risk indicator or predictive biomarkers), if a disease already exists (diagnostic biomarker), or how such a disease may develop in an individual case regardless of the type of treatment (prognostic biomarker). predictive biomarkers help to assess the most likely response to a particular treatment type, while prognostic markers shows the progression of disease with or without treatment. in contrast, drug-related biomarkers indicate whether a drug will be effective in a specific patient and how the patient's body will process it. in addition to long-known parameters, such as those included and objectively measured in a blood count, there are numerous novel biomarkers used in the various medical specialties. currently, intensive work is taking place on the discovery and development of innovative and more effective biomarkers. these "new" biomarkers have become the basis for preventive medicine, meaning medicine that recognises diseases or the risk of disease early, and takes specific countermeasures to prevent the development of disease. biomarkers are also seen as the key to personalised medicine, treatments individually tailored to specific patients for highly efficient intervention in disease processes. often, such biomarkers indicate changes in metabolic processes. the "classic" biomarker in medicine is a laboratory parameter that the doctor can use to help make decisions in making a diagnosis and selecting a course of treatment. for example, the detection of certain autoantibodies in patient blood is a reliable biomarker for autoimmune disease, and the detection of rheumatoid factors has been an important diagnostic marker for rheumatoid arthritis (ra) for over 50 years. for the diagnosis of this autoimmune disease the antibodies against the bodies own citrullinated proteins are of particular value. these acpas, (acpa stands for anti-citrullinated protein/peptide antibody) can be detected in the blood before the first symptoms of ra appear. they are thus highly valuable biomarkers for the early diagnosis of this autoimmune disease. in addition, they indicate if the disease threatens to be severe with serious damage to the bones and joints, which is an important tool for the doctor when providing a diagnosis and developing a treatment plan. there are also more and more indications that acpas can be very useful in monitoring the success of treatment for ra. this would make possible the accurate use of modern treatments with biologicals. physicians hope to soon be able to individually tailor rheumatoid arthritis treatments for each patient. according to häupl t. et al. prediction of response to treatment will become the most important aim of biomarker research in medicine. with the growing number of new biological agents, there is increasing pressure to identify molecular parameters such as acpas that will not only guide the therapeutic decision but also help to define the most important targets for which new biological agents should be tested in clinical studies. an nih study group committed to the following definition in 1998: "a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention." in the past, biomarkers were primarily physiological indicators such as blood pressure or heart rate. more recently, biomarker is becoming a synonym for molecular biomarker, such as elevated prostate specific antigen as a molecular biomarker for prostate cancer, or using enzyme assays as liver function tests. there has recently been heightened interest in the relevance of biomarkers in oncology, including the role of kras in colorectal cancer and other egfr-associated cancers. in patients whose tumors express the mutated kras gene, the kras protein, which forms part of the egfr signaling pathway, is always 'turned on'. this overactive egfr signaling means that signaling continues downstream – even when the upstream signaling is blocked by an egfr inhibitor, such as cetuximab (erbitux) – and results in continued cancer cell growth and proliferation. testing a tumor for its kras status (wild-type vs. mutant) helps to identify those patients who will benefit most from treatment with cetuximab. currently, effective treatment is available for only a small percentage of cancer patients. in addition, many cancer patients are diagnosed at a stage where the cancer has advanced too far to be treated. biomarkers have the ability to greatly enhance cancer detection and the drug development process. in addition, biomarkers will enable physicians to develop individualized treatment plans for their cancer patients; thus allowing doctors to tailor drugs specific to their patient's tumor type. by doing so, drug response rate will improve, drug toxicity will be limited and costs associated with testing various therapies and the ensuing treatment for side effects will decrease. biomarkers also cover the use of molecular indicators of environmental exposure in epidemiologic studies such as human papilloma virus or certain markers of tobacco exposure such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (nnk). to date no biomarkers have been established for head and neck cancer. biomarker requirements for chronic diseases, whose treatment may require patients to take medications for years, accurate diagnosis is particularly important, especially when strong side effects are expected from the treatment. in these cases, biomarkers are becoming more and more important, because they can confirm a difficult diagnosis or even make it possible in the first place. a number of diseases, such as alzheimer's disease or rheumatoid arthritis, often begin with an early, symptom-free phase. in such symptom-free patients there may be more or less probability of actually developing symptoms. in these cases, biomarkers help to identify high-risk individuals reliably and in a timely manner so that they can either be treated before onset of the disease or as soon as possible thereafter. in order to use a biomarker for diagnostics, the sample material must be as easy to obtain as possible. this may be a blood sample taken by a doctor, a urine or saliva sample, or a drop of blood like those diabetes patients extract from their own fingertips for regular blood-sugar monitoring. for rapid initiation of treatment, the speed with which a result is obtained from the biomarker test is critical. a rapid test, which delivers a result after only a few minutes, is optimal. this makes it possible for the physician to discuss with the patient how to proceed and if necessary to start treatment immediately after the test. naturally, the detection method for a biomarker must be accurate and as easy to carry out as possible. the results from different laboratories may not differ significantly from each other, and the biomarker must naturally have proven its effectiveness for the diagnosis, prognosis, and risk assessment of the affected diseases in independent studies. a biomarker for clinical use needs good sensitivity and specificity e.g. ≥0.9, and good specificity e.g. ≥0.9 although they should be chosen with the population in mind so positive predictive value and negative predictive value are more relevant. biomarker classification and application biomarkers can be classified based on different criteria. based on their characteristics they can be classified as imaging biomarkers (ct, pet, mri) or molecular biomarkers with three subtypes: volatile, like breath, body fluid, or biopsy biomarkers. molecular biomarkers refer to non-imaging biomarkers that have biophysical properties, which allow their measurements in biological samples (e.g., plasma, serum, cerebrospinal fluid, bronchoalveolar lavage, biopsy) and include nucleic acids-based biomarkers such as gene mutations or polymorphisms and quantitative gene expression analysis, peptides, proteins, lipids metabolites, and other small molecules. biomarkers can also be classified based on their application such as diagnostic biomarkers (i.e., cardiac troponin for the diagnosis of myocardial infarction), staging of disease biomarkers (i.e., brain natriuretic peptide for congestive heart failure), disease prognosis biomarkers (cancer biomarkers), and biomarkers for monitoring the clinical response to an intervention (hbalc for antidiabetic treatment). another category of biomarkers includes those used in decision making in early drug development. for instance, pharmacodynamic (pd) biomarkers are markers of a certain pharmacological response, which are of special interest in dose optimization studies. types biomarkers validated by genetic and molecular biology methods can be classified into three types. type 0 — natural history markers type 1 — drug activity markers type 2 — surrogate markers discovery of molecular biomarkers main article: biomarker discovery molecular biomarkers have been defined as biomarkers that can be discovered using basic and acceptable platforms such as genomics and proteomics. many genomic and proteomics techniques are available for biomarker discovery and a few techniques that are recently being used can be found on that page. apart from genomics and proteomics platforms biomarker assay techniques, metabolomics, lipidomics, glycomics, and secretomics are the most commonly used as techniques in identification of biomarkers. imaging biomarkers main article: imaging biomarker many new biomarkers are being developed that involve imaging technology. imaging biomarkers have many advantages. they are usually noninvasive, and they produce intuitive, multidimensional results. yielding both qualitative and quantitative data, they are usually relatively comfortable for patients. when combined with other sources of information, they can be very useful to clinicians seeking to make a diagnosis. cardiac imaging is an active area of biomarker research. coronary angiography, an invasive procedure requiring catheterization, has long been the gold standard for diagnosing arterial stenosis, but scientists and doctors hope to develop noninvasive techniques. many believe that cardiac computed tomography (ct) has great potential in this area, but researchers are still attempting to overcome problems related to "calcium blooming," a phenomenon in which calcium deposits interfere with image resolution. other intravascular imaging techniques involving magnetic resonance imaging (mri), optical coherence tomography (oct), and near infrared spectroscopy are also being investigated. another new imaging biomarker involves radiolabeled fludeoxyglucose. positron emission tomography (pet) can be used to measure where in the body cells take up glucose. by tracking glucose, doctors can find sites of inflammation because macrophages there take up glucose at high levels. tumors also take up a lot of glucose, so the imaging